{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:49:39Z","timestamp":1792651779014,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01175-z","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T18:42:44Z","timestamp":1760467364000},"page":"917-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Decade After Approval of the First CDK4\/6 Inhibitor: A Look Back at Palbociclib\u2019s Journey from Discovery to Approval and What\u2019s Next in CDK Inhibition in Breast Cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Richard S.","family":"Finn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"7","key":"1175_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547\u201366. https:\/\/doi.org\/10.1038\/nrd2907.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1175_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):11. https:\/\/doi.org\/10.1038\/s41392-024-02080-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1175_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493\u2013502. https:\/\/doi.org\/10.1038\/nrd839.","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"1175_CR4","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.3390\/ijms21186479","volume":"21","author":"M Piezzo","year":"2020","unstructured":"Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, et al. Targeting cell cycle in breast cancer: CDK4\/6 inhibitors. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21186479.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1175_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1185\/03007995.2014.908829","volume":"30","author":"E Swallow","year":"2014","unstructured":"Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)\/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002\u20132012. Curr Med Res Opin. 2014;30(8):1537\u201345. https:\/\/doi.org\/10.1185\/03007995.2014.908829.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41416-020-0979-3","volume":"123","author":"J Simon","year":"2020","unstructured":"Simon J, Chaix M, Billa O, Kamga AM, Roignot P, Ladoire S, et al. Survival in patients with HR+\/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study. Br J Cancer. 2020;123(7):1071\u20137. https:\/\/doi.org\/10.1038\/s41416-020-0979-3.","journal-title":"Br J Cancer"},{"issue":"5","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. https:\/\/doi.org\/10.1186\/bcr2419.","journal-title":"Breast Cancer Res"},{"issue":"21","key":"1175_CR8","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.ccr-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21(21):4760\u20136. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1185.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1175_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(14)71159-3.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1175_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"issue":"4","key":"1175_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0.","journal-title":"Lancet Oncol"},{"key":"1175_CR12","unstructured":"US FDA. Ribociclib (Kisqali). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ribociclib-kisqali. Accessed 25 Mar 2025."},{"key":"1175_CR13","unstructured":"US FDA. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer. Accessed 25 Mar 2025."},{"issue":"18","key":"1175_CR14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"32","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-024-07469-6","volume":"208","author":"A Brufsky","year":"2024","unstructured":"Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, et al. Trends in HR+ metastatic breast cancer survival before and after CDK4\/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024;208(2):223\u201335. https:\/\/doi.org\/10.1007\/s10549-024-07469-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1175_CR17","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines(R) Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031.","DOI":"10.6004\/jnccn.2023.0031"},{"key":"1175_CR18","unstructured":"Fineline Cube. Jiangsu Hengrui\u2019s dalpiciclib approved for initial therapy in HR+, HER2- breast cancer. 2023. https:\/\/flcube.com\/?p=17169. Accessed 15 July 2025."},{"key":"1175_CR19","unstructured":"Fineline Cube. Genor biopharma gains NMPA approval for CDK4\/6 inhibitor lerociclib in China. https:\/\/flcube.com\/?p=34493. Accessed 15 July 2025."},{"issue":"9","key":"1175_CR20","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1021\/acs.jmedchem.1c02190","volume":"65","author":"Z Xie","year":"2022","unstructured":"Xie Z, Hou S, Yang X, Duan Y, Han J, Wang Q, et al. Lessons learned from past cyclin-dependent kinase drug discovery efforts. J Med Chem. 2022;65(9):6356\u201389. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02190.","journal-title":"J Med Chem"},{"key":"1175_CR21","doi-asserted-by":"publisher","unstructured":"Jhaveri K, Marme F. Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev. 2024;123:102670. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102670.","DOI":"10.1016\/j.ctrv.2023.102670"},{"key":"1175_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ctrv.2017.12.002","volume":"63","author":"GA Ba\u015faran","year":"2018","unstructured":"Ba\u015faran GA, Twelves C, Di\u00e9ras V, Cort\u00e9s J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive\/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144\u201355. https:\/\/doi.org\/10.1016\/j.ctrv.2017.12.002.","journal-title":"Cancer Treat Rev"},{"key":"1175_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall\u2019Acqua A, Vecchione A, Baldassarre G, et al. CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review. Front Oncol. 2022;12:891580. https:\/\/doi.org\/10.3389\/fonc.2022.891580.","journal-title":"Front Oncol"},{"key":"1175_CR24","unstructured":"US FDA. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive. Accessed 8 Dec 2024."},{"issue":"9","key":"1175_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091422","volume":"13","author":"IM Stanciu","year":"2023","unstructured":"Stanciu IM, Parosanu AI, Nitipir C. An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast cancer\u2014a systematic review of randomized phase II and III clinical trials. Biomolecules. 2023;13(9):1422. https:\/\/doi.org\/10.3390\/biom13091422.","journal-title":"Biomolecules"},{"issue":"5\u20136","key":"1175_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1023\/a:1022077317801","volume":"22","author":"T Hunt","year":"2002","unstructured":"Hunt T. Nobel lecture. Protein synthesis, proteolysis, and cell cycle transitions. Biosci Rep. 2002;22(5\u20136):465\u201386. https:\/\/doi.org\/10.1023\/a:1022077317801.","journal-title":"Biosci Rep"},{"issue":"5\u20136","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1023\/a:1022017701871","volume":"22","author":"PM Nurse","year":"2002","unstructured":"Nurse PM. Nobel lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep. 2002;22(5\u20136):487\u201399. https:\/\/doi.org\/10.1023\/a:1022017701871.","journal-title":"Biosci Rep"},{"issue":"5192","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1126\/science.7997877","volume":"266","author":"LH Hartwell","year":"1994","unstructured":"Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266(5192):1821\u20138. https:\/\/doi.org\/10.1126\/science.7997877.","journal-title":"Science"},{"issue":"7317","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.323.7317.823","volume":"323","author":"G Watts","year":"2001","unstructured":"Watts G. Three cell cycle scientists win Nobel prize. BMJ. 2001;323(7317):823.","journal-title":"BMJ"},{"issue":"2","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0092-8674(92)90360-o","volume":"71","author":"H Matsushime","year":"1992","unstructured":"Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3\/cdk4) for mammalian D type G1 cyclins. Cell. 1992;71(2):323\u201334. https:\/\/doi.org\/10.1016\/0092-8674(92)90360-o.","journal-title":"Cell"},{"issue":"3","key":"1175_CR31","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1128\/mcb.14.3.2077-2086.1994","volume":"14","author":"M Meyerson","year":"1994","unstructured":"Meyerson M, Harlow E. Identification of G1 kinase activity for CDK6, a novel cyclin D partner. Mol Cell Biol. 1994;14(3):2077\u201386. https:\/\/doi.org\/10.1128\/mcb.14.3.2077-2086.1994.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1175_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130\u201346. https:\/\/doi.org\/10.1038\/nrd4504.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1175_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.cd-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353\u201367. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0894.","journal-title":"Cancer Discov"},{"issue":"11","key":"1175_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911\u201325. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.002.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1175_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","volume":"9","author":"Q Yu","year":"2006","unstructured":"Yu Q, Sicinska E, Geng Y, Ahnstr\u00f6m M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9(1):23\u201332. https:\/\/doi.org\/10.1016\/j.ccr.2005.12.012.","journal-title":"Cancer Cell"},{"issue":"1","key":"1175_CR36","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.1038\/s41467-024-50891-z","volume":"15","author":"R D\u00fcster","year":"2024","unstructured":"D\u00fcster R, Anand K, Binder SC, Schmitz M, Gatterdam K, Fisher RP, et al. Structural basis of Cdk7 activation by dual T-loop phosphorylation. Nat Commun. 2024;15(1):6597. https:\/\/doi.org\/10.1038\/s41467-024-50891-z.","journal-title":"Nat Commun"},{"issue":"1","key":"1175_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4161\/cc.10.1.14364","volume":"10","author":"DS Yu","year":"2011","unstructured":"Yu DS, Cortez D. A role for CDK9-cyclin K in maintaining genome integrity. Cell Cycle. 2011;10(1):28\u201332. https:\/\/doi.org\/10.4161\/cc.10.1.14364.","journal-title":"Cell Cycle"},{"issue":"9","key":"1175_CR38","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","volume":"65","author":"Z Shi","year":"2022","unstructured":"Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, et al. From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J Med Chem. 2022;65(9):6390\u2013418. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02064.","journal-title":"J Med Chem"},{"issue":"5","key":"1175_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1345\/aph.1A162","volume":"36","author":"S Zhai","year":"2002","unstructured":"Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother. 2002;36(5):905\u201311. https:\/\/doi.org\/10.1345\/aph.1A162.","journal-title":"Ann Pharmacother"},{"issue":"12 Pt 2","key":"1175_CR40","doi-asserted-by":"publisher","first-page":"4270s","DOI":"10.1158\/1078-0432.ccr-040020","volume":"10","author":"GI Shapiro","year":"2004","unstructured":"Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10(12 Pt 2):4270s-s4275. https:\/\/doi.org\/10.1158\/1078-0432.ccr-040020.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1175_CR41","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","volume":"84","author":"G Kaur","year":"1992","unstructured":"Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86\u20138275. J Natl Cancer Inst. 1992;84(22):1736\u201340. https:\/\/doi.org\/10.1093\/jnci\/84.22.1736.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1175_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020293","volume":"14","author":"T Ettl","year":"2022","unstructured":"Ettl T, Schulz D, Bauer RJ. The renaissance of cyclin dependent kinase inhibitors. Cancers (Basel). 2022;14(2):293. https:\/\/doi.org\/10.3390\/cancers14020293.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1175_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3978\/j.issn.2305-5839.2015.03.61","volume":"3","author":"J Cicenas","year":"2015","unstructured":"Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, et al. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3(10):135. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.61.","journal-title":"Ann Transl Med."},{"issue":"5","key":"1175_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett. 2010;1(5):204\u20138. https:\/\/doi.org\/10.1021\/ml100051d.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"1175_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.apsb.2020.05.001","volume":"11","author":"K Yuan","year":"2021","unstructured":"Yuan K, Wang X, Dong H, Min W, Hao H, Yang P. Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021;11(1):30\u201354. https:\/\/doi.org\/10.1016\/j.apsb.2020.05.001.","journal-title":"Acta Pharm Sin B"},{"issue":"6199","key":"1175_CR46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.345.6199.865","volume":"345","author":"K Garber","year":"2014","unstructured":"Garber K. The cancer drug that almost wasn\u2019t. Science. 2014;345(6199):865\u20137. https:\/\/doi.org\/10.1126\/science.345.6199.865.","journal-title":"Science"},{"issue":"5","key":"1175_CR47","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913\u201335.","journal-title":"Am J Cancer Res"},{"key":"1175_CR48","unstructured":"Pfizer Laboratories. IBRANCE (palbociclib) tablets, for oral use. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12921. Accessed 31 Mar 2025."},{"issue":"11","key":"1175_CR49","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1175_CR50","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/bjc.2011.177","volume":"104","author":"GK Schwartz","year":"2011","unstructured":"Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2\/1). Br J Cancer. 2011;104(12):1862\u20138. https:\/\/doi.org\/10.1038\/bjc.2011.177.","journal-title":"Br J Cancer"},{"issue":"2","key":"1175_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.ccr-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568\u201376. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-0509.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1175_CR52","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597\u2013607. https:\/\/doi.org\/10.1182\/blood-2011-10-388298.","journal-title":"Blood"},{"issue":"4","key":"1175_CR53","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/jco.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17(4):1244. https:\/\/doi.org\/10.1200\/jco.1999.17.4.1244.","journal-title":"J Clin Oncol"},{"issue":"24_Suppl","key":"1175_CR54","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/0008-5472.SABCS-09-5069","volume":"69","author":"R Finn","year":"2009","unstructured":"Finn R, Hurvitz S, Allison M, Applebaum S, Glaspy J, DiCarlo B, et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4\/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Cancer Res. 2009;69(24_Suppl):5069. https:\/\/doi.org\/10.1158\/0008-5472.SABCS-09-5069.","journal-title":"Cancer Res"},{"key":"1175_CR55","unstructured":"ClinicalTrials.gov. Study of letrozole with or without palbociclib (PD-0332991) for the first-line treatment of hormone-receptor positive advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT00721409. Accessed 31 Mar 2025."},{"key":"1175_CR56","doi-asserted-by":"publisher","unstructured":"Finn RS, Crown JP, Boer K, Lang I, Parikh RJ, Breazna A, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4\/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (BC). Ann Oncol. 2012;23(Suppl 2):ii43\u2013ii5. https:\/\/doi.org\/10.1093\/annonc\/mds045.","DOI":"10.1093\/annonc\/mds045"},{"key":"1175_CR57","unstructured":"Pfizer.com. Pfizer\u2019s palbociclib (PD-0332991) receives Food and Drug Administration breakthrough therapy designation for potential treatment of patients with breast cancer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_s_palbociclib_pd_0332991_receives_food_and_drug_administration_breakthrough_therapy_designation_for_potential_treatment_of_patients_with_breast_cancer. Accessed 31 Mar 2025."},{"key":"1175_CR58","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.2147\/ott.s77033","volume":"9","author":"K Bo\u00e9r","year":"2016","unstructured":"Bo\u00e9r K. Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive\/human epidermal growth factor 2-negative breast cancer. Onco Targets Ther. 2016;9:6119\u201325. https:\/\/doi.org\/10.2147\/ott.s77033.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"1175_CR59","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/jco.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000. https:\/\/doi.org\/10.1200\/jco.23.00137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1175_CR60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719\u201329. https:\/\/doi.org\/10.1007\/s10549-018-05125-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1175_CR61","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdy012","volume":"29","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Dieras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888\u201394. https:\/\/doi.org\/10.1093\/annonc\/mdy012.","journal-title":"Ann Oncol"},{"issue":"4","key":"1175_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104497","volume":"10","author":"N Harbeck","year":"2025","unstructured":"Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, et al. Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial. ESMO Open. 2025;10(4):104497. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104497.","journal-title":"ESMO Open"},{"issue":"3","key":"1175_CR63","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"issue":"20","key":"1175_CR64","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"key":"1175_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.08.011","volume":"104","author":"M Cristofanilli","year":"2018","unstructured":"Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur J Cancer. 2018;104:21\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2018.08.011.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1175_CR66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","volume":"27","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andre F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047\u201354. https:\/\/doi.org\/10.1093\/annonc\/mdw139.","journal-title":"Ann Oncol"},{"key":"1175_CR67","unstructured":"US FDA. Palbociclib (IBRANCE). 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/palbociclib-ibrance. Accessed 29 Jan 2025."},{"key":"1175_CR68","unstructured":"Pfizer. U.S. FDA approves IBRANCE\u00ae (palbociclib) for the treatment of men with HR+, HER2\u2212 metastatic breast cancer. 2019. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer. Accessed 6 Mar 2025."},{"key":"1175_CR69","unstructured":"FIERCE Pharma. In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion. https:\/\/www.fiercepharma.com\/pharma\/mysterious-approval-pfizer-quietly-wins-ibrance-breast-cancer-expansion-after-fda-requested. Accessed 3 Apr 2025."},{"key":"1175_CR70","unstructured":"Pfizer. Pfizer presents positive real-world evidence for first-line IBRANCE\u00ae (palbociclib) combination therapy in HR+, HER2\u2212 metastatic breast cancer at ESMO Breast Cancer 2022. 2022. https:\/\/www.pfizer.com\/news\/announcements\/pfizer-presents-positive-real-world-evidence-first-line-ibrancer-palbociclib. Accessed 29 Jan 2025."},{"issue":"3","key":"1175_CR71","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11523-023-00968-4","volume":"18","author":"A Brufsky","year":"2023","unstructured":"Brufsky A, Gallagher C. P-REALITY x: a real-world analysis of palbociclib plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer-a podcast. Target Oncol. 2023;18(3):321\u20136. https:\/\/doi.org\/10.1007\/s11523-023-00968-4.","journal-title":"Target Oncol"},{"issue":"1","key":"1175_CR72","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):114. https:\/\/doi.org\/10.1038\/s41523-022-00479-x.","journal-title":"NPJ Breast Cancer"},{"key":"1175_CR73","doi-asserted-by":"publisher","first-page":"1237751","DOI":"10.3389\/fonc.2023.1237751","volume":"13","author":"A Brufsky","year":"2023","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751. https:\/\/doi.org\/10.3389\/fonc.2023.1237751.","journal-title":"Front Oncol"},{"issue":"3","key":"1175_CR74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","volume":"19","author":"E Brain","year":"2024","unstructured":"Brain E, Chen C, Simon S, Pasupuleti V, Pfitzer KV, Gelmon KA. Palbociclib in older patients with advanced\/metastatic breast cancer: a systematic review. Target Oncol. 2024;19(3):303\u201320. https:\/\/doi.org\/10.1007\/s11523-024-01046-z.","journal-title":"Target Oncol"},{"issue":"10","key":"1175_CR75","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/oncolo\/oyad209","volume":"28","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Real-world effectiveness of palbociclib plus aromatase inhibitors in African American patients with metastatic breast cancer. Oncologist. 2023;28(10):866\u201374. https:\/\/doi.org\/10.1093\/oncolo\/oyad209.","journal-title":"Oncologist"},{"issue":"21","key":"1175_CR76","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/cancers15215268","volume":"15","author":"A Brufsky","year":"2023","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Palbociclib combined with an aromatase inhibitor in patients with breast cancer with lung or liver metastases in US clinical practice. Cancers (Basel). 2023;15(21):5268. https:\/\/doi.org\/10.3390\/cancers15215268.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"1175_CR77","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/oncolo\/oyae273","volume":"29","author":"A Brufsky","year":"2024","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, et al. Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024;29(12):1032\u201343. https:\/\/doi.org\/10.1093\/oncolo\/oyae273.","journal-title":"Oncologist"},{"issue":"7","key":"1175_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae291","volume":"30","author":"D Tripathy","year":"2025","unstructured":"Tripathy D, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi M, et al. Real-world effectiveness of palbociclib plus endocrine therapy in HR+\/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist. 2025;30(7):oyae291. https:\/\/doi.org\/10.1093\/oncolo\/oyae291.","journal-title":"Oncologist"},{"issue":"12","key":"1175_CR79","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.clinthera.2022.11.004","volume":"44","author":"K Mycock","year":"2022","unstructured":"Mycock K, Hanson KA, Taylor-Stokes G, Milligan G, Atkinson C, Mitra D, et al. Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the Ibrance Real World Insights Study. Clin Ther. 2022;44(12):1588\u2013601. https:\/\/doi.org\/10.1016\/j.clinthera.2022.11.004.","journal-title":"Clin Ther"},{"issue":"10","key":"1175_CR80","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"issue":"4","key":"1175_CR81","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"issue":"24","key":"1175_CR82","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/jco.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372. https:\/\/doi.org\/10.1200\/jco.2018.78.9909.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1175_CR83","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaoncol.2020.1518","volume":"6","author":"GW Sledge Jr.","year":"2020","unstructured":"Sledge GW Jr., Frenzel M. Analysis of overall survival benefit of abemaciclib plus fulvestrant in hormone receptor-positive, ERBB2-negative breast cancer-reply. JAMA Oncol. 2020;6(7):1122\u20133. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1518.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1175_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in US routine clinical practice. ESMO Open. 2025;10(9):105570. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105570.","journal-title":"ESMO Open."},{"issue":"1","key":"1175_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10(1):104103. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104103.","journal-title":"ESMO Open"},{"issue":"7","key":"1175_CR86","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","volume":"36","author":"L Provenzano","year":"2025","unstructured":"Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, et al. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol. 2025;36(7):762\u201374. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.023.","journal-title":"Ann Oncol"},{"issue":"12","key":"1175_CR87","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","volume":"7","author":"A Llombart-Cussac","year":"2021","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ru\u00edz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol. 2021;7(12):1791\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4301.","journal-title":"JAMA Oncol"},{"key":"1175_CR88","doi-asserted-by":"publisher","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda J, Ezquerra M, Dalenc F, Gil M, Ruiz-Borrego M, et al. Abstract RF01-03: PARSIFAL-LONG: extended follow-up of hormone receptor-positive\/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study. Cancer Res. 2024;84(9_Suppl):RF01-3. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-RF01-03.","DOI":"10.1158\/1538-7445.SABCS23-RF01-03"},{"key":"1175_CR89","doi-asserted-by":"crossref","unstructured":"Loibl S, Thill M, Rey J, Rautenberg B, Bjelic-Radisic V, Decker T, et al. LB1-03: Primary results of the randomised phase III trial comparing first line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy\u2014PADMA study. Clin Cancer Res. 2025;31(12_Supplement):LB1-03. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-LB1-03","DOI":"10.1158\/1557-3265.SABCS24-LB1-03"},{"issue":"17","key":"1175_CR90","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584\u201396. https:\/\/doi.org\/10.1056\/NEJMoa2404625.","journal-title":"N Engl J Med"},{"key":"1175_CR91","unstructured":"Metzger O, Mandrekar S, Demichele A, Gianni L, Gligorov J, Lim E, et al. AFT-38 PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive (HR+)\/HER2\u2212positive metastatic breast cancer. Oral presentation at SABCS 2024. Available at: https:\/\/sabcs.org\/Portals\/0\/Documents\/PATINA_Abstract_12-11-24.pdf?ver=6NaxdWhjPHoc7aD3kzrO4Q%3d%3d. Accessed 8 September 2025."},{"key":"1175_CR92","doi-asserted-by":"publisher","first-page":"175883592311872","DOI":"10.1177\/17588359231187201","volume":"15","author":"M Pegram","year":"2023","unstructured":"Pegram M, Pietras R, Dang CT, Murthy R, Bachelot T, Janni W, et al. Evolving perspectives on the treatment of HR+\/HER2+ metastatic breast cancer. Ther Adv Med Oncol. 2023;15:17588359231187200. https:\/\/doi.org\/10.1177\/17588359231187201.","journal-title":"Ther Adv Med Oncol"},{"key":"1175_CR93","doi-asserted-by":"publisher","first-page":"S362","DOI":"10.1016\/j.annonc.2024.08.298","volume":"35","author":"W Janni","year":"2024","unstructured":"Janni W, Fehm TN, Mueller V, de Gregorio AMB, Decker T, Hartkopf AD, et al. 350MO omission of chemotherapy and addition of the CDK4\/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer\u2014second interim efficacy analysis of the randomized phase III DETECT V trial. Ann Oncol. 2024;35:S362. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.298.","journal-title":"Ann Oncol"},{"issue":"6","key":"1175_CR94","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/s1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(20)30112-1.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1175_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411791","volume":"24","author":"JS Lee","year":"2023","unstructured":"Lee JS, Hackbart H, Cui X, Yuan Y. CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions. Int J Mol Sci. 2023;24(14):11791. https:\/\/doi.org\/10.3390\/ijms241411791.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1175_CR96","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D, Lambertini M, Dess\u00ec M, Denaro N, Bardanzellu F, Garrone O, et al. CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol. 2023;50(6):131\u20139. https:\/\/doi.org\/10.1053\/j.seminoncol.2024.01.002.","journal-title":"Semin Oncol"},{"key":"1175_CR97","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00002","volume":"6","author":"US Asghar","year":"2022","unstructured":"Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer. JCO Precis Oncol. 2022;6:e2100002. https:\/\/doi.org\/10.1200\/po.21.00002.","journal-title":"JCO Precis Oncol"},{"key":"1175_CR98","unstructured":"US FDA. FDA expands early breast cancer indication for abemaciclib with endocrine therapy. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy. Accessed 7 Mar 2025."},{"key":"1175_CR99","unstructured":"US FDA. FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ribociclib-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-early-high-risk. Accessed 7 Mar 2025."},{"issue":"3","key":"1175_CR100","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/jco.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol. 2022;40(3):282\u201393. https:\/\/doi.org\/10.1200\/jco.21.02554.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1175_CR101","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/jco.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 2021;39(14):1518\u201330. https:\/\/doi.org\/10.1200\/jco.20.03639.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1175_CR102","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1021\/acs.jmedchem.4c01686","volume":"68","author":"C Jiang","year":"2025","unstructured":"Jiang C, Ye Y, Kang W, Yang J, He Z, Cao Q, et al. Elucidating binding selectivity in cyclin-dependent kinases 4, 6, and 9: development of highly potent and selective CDK4\/9 inhibitors. J Med Chem. 2025;68(2):1499\u2013510. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01686.","journal-title":"J Med Chem"},{"key":"1175_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol. 2024;196:104324. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104324.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1175_CR104","doi-asserted-by":"publisher","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464\u201381 e14. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.006.","DOI":"10.1016\/j.ccell.2025.02.006"},{"issue":"16_suppl","key":"1175_CR105","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1200\/JCO.2024.42.16_suppl.3108","volume":"42","author":"A Giordano","year":"2024","unstructured":"Giordano A, Sharma M, Williams A, Schmid P, Flores Diaz DF, Magallanes M, et al. First-in-human phase 1\/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): updated safety data in patients with HR+\/HER2\u2212 mBC. J Clin Oncol. 2024;42(16_suppl):3108. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3108.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1175_CR106","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2023.41.16_suppl.3010","volume":"41","author":"TA Yap","year":"2023","unstructured":"Yap TA, Elhaddad AM, Grisham RN, Hamm JT, Marks DK, Shapiro G, et al. First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2- breast cancer. J Clin Oncol. 2023;41(16_suppl):3010. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3010.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1175_CR107","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023;9(1):74. https:\/\/doi.org\/10.1038\/s41523-023-00578-3.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"1175_CR108","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41416-024-02589-8","volume":"130","author":"X Song","year":"2024","unstructured":"Song X, Fang C, Dai Y, Sun Y, Qiu C, Lin X, et al. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. Br J Cancer. 2024;130(8):1239\u201348. https:\/\/doi.org\/10.1038\/s41416-024-02589-8.","journal-title":"Br J Cancer"},{"issue":"1","key":"1175_CR109","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14(1):4444. https:\/\/doi.org\/10.1038\/s41467-023-40061-y.","journal-title":"Nat Commun"},{"key":"1175_CR110","unstructured":"ClinicalTrials.gov. AKT inhibitor, ipatasertib, with endocrine and CDK 4\/ 6 inhibitor for patients with metastatic breast cancer (TAKTIC). https:\/\/clinicaltrials.gov\/study\/NCT03959891. Accessed 8 July 2025."},{"key":"1175_CR111","unstructured":"ClinicalTrials.gov. Fulvestrant, ipatasertib and CDK4\/6 inhibition in metastatic ER+\/HER2- breast cancer patients without ctDNA suppression (FAIM). https:\/\/clinicaltrials.gov\/study\/NCT04920708. Accessed 8 July 2025."},{"key":"1175_CR112","unstructured":"ClinicalTrials.gov. Palbociclib in combination with bicalutamide for the treatment of AR(+) metastatic breast cancer (MBC). https:\/\/clinicaltrials.gov\/study\/NCT02605486. Accessed 8 July 2025."},{"key":"1175_CR113","unstructured":"ClinicalTrials.gov. A phase Ib\/II study confirmed inhibition of autophagy synergizes anti-tumor effect of high dose CDK4\/6i. https:\/\/clinicaltrials.gov\/study\/NCT05953350. Accessed 8 July 2025."},{"key":"1175_CR114","unstructured":"ClinicalTrials.gov. Avelumab or hydroxychloroquine with or without palbociclib to eliminate dormant breast cancer (PALAVY). https:\/\/clinicaltrials.gov\/study\/NCT04841148. Accessed 8 July 2025."},{"key":"1175_CR115","unstructured":"ClinicalTrials.gov. Palbociclib, letrozole & venetoclax in ER and BCL-2 positive breast cancer (PALVEN). https:\/\/clinicaltrials.gov\/study\/NCT03900884. Accessed 8 July 2025."},{"key":"1175_CR116","unstructured":"ClinicalTrials.gov. PF-07104091 as a single agent and in combination therapy. https:\/\/clinicaltrials.gov\/study\/NCT04553133. Accessed 13 Mar 2025."},{"key":"1175_CR117","unstructured":"ClinicalTrials.gov. Study of AVZO-021 in patients with advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05867251. Accessed 2 Apr 2025."},{"key":"1175_CR118","unstructured":"ClinicalTrials.gov. Study of INCB123667 in subjects with advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05238922. Accessed 2 Apr 2025."},{"key":"1175_CR119","unstructured":"ClinicalTrials.gov. A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in participants with selected advanced or metastatic solid tumors (CYCAD-1). https:\/\/clinicaltrials.gov\/study\/NCT06188520. Accessed 2 Apr 2025."},{"key":"1175_CR120","unstructured":"ClinicalTrials.gov. A phase 1 study of BMS-986500 as monotherapy or combination therapy in advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT06997029. Accessed 8 July 2025."},{"key":"1175_CR121","unstructured":"ClinicalTrials.gov. ONO-4578-06: phase I study of ONO-4578 and letrozole plus CDK4\/6 inhibitors in breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06570031. Accessed 8 July 2025."},{"key":"1175_CR122","unstructured":"ClinicalTrials.gov. Targeted therapy directed by genetic testing in treating patients with locally advanced or advanced solid tumors, the ComboMATCH screening trial. https:\/\/clinicaltrials.gov\/study\/NCT05564377. Accessed 8 July 2025."},{"key":"1175_CR123","unstructured":"ClinicalTrials.gov. Anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, HER2-positive metastatic breast. https:\/\/clinicaltrials.gov\/study\/NCT03304080. Accessed 8 July 2025."},{"key":"1175_CR124","unstructured":"ClinicalTrials.gov. Palbociclib combine with anti-HER2 therapy in triple positive ABC. https:\/\/clinicaltrials.gov\/study\/NCT05969184. Accessed 8 July 2025."},{"key":"1175_CR125","unstructured":"ClinicalTrials.gov. Randomized, open label, clinical study of the targeted therapy, palbociclib, to treat metastatic breast cancer (PATINA). https:\/\/clinicaltrials.gov\/study\/NCT02947685. Accessed 8 July 2025."},{"key":"1175_CR126","unstructured":"ClinicalTrials.gov. A study of ZW25 (zanidatamab) with palbociclib plus fulvestrant in patients with HER2+\/HR+ advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT04224272. Accessed 8 July 2025."},{"key":"1175_CR127","unstructured":"ClinicalTrials.gov. Study of PF-07248144 in advanced or metastatic solid tumors (KAT6). https:\/\/clinicaltrials.gov\/study\/NCT04606446. Accessed 8 July 2025."},{"key":"1175_CR128","unstructured":"ClinicalTrials.gov. A study of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant for the treatment of advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06941142. Accessed 8 July 2025."},{"key":"1175_CR129","unstructured":"ClinicalTrials.gov. A study of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant for the treatment of advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06856200. Accessed 8 July 2025."},{"key":"1175_CR130","unstructured":"ClinicalTrials.gov. HOPE: olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, HR+, HER2-metastatic breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT03685331. Accessed 8 July 2025."},{"key":"1175_CR131","unstructured":"ClinicalTrials.gov. Palbociclib and pembrolizumab In central nervous system metastases. https:\/\/clinicaltrials.gov\/study\/NCT02896335. Accessed 8 July 2025."},{"key":"1175_CR132","unstructured":"ClinicalTrials.gov. Pembrolizumab, endocrine therapy, and palbociclib in treating postmenopausal patients with newly diagnosed metastatic stage IV estrogen receptor positive breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT02778685. Accessed 15 July 2025."},{"key":"1175_CR133","unstructured":"ClinicalTrials.gov. PAveMenT: palbociclib and avelumab in metastatic AR+ triple negative breast cancer (PAveMenT). https:\/\/clinicaltrials.gov\/study\/NCT04360941. Accessed 8 July 2025."},{"key":"1175_CR134","unstructured":"ClinicalTrials.gov. Gedatolisib plus fulvestrant with or without palbociclib vs standard-of-care for the treatment of patients with advanced or metastatic HR+\/HER2- breast cancer (VIKTORIA-1). https:\/\/clinicaltrials.gov\/study\/NCT05501886. Accessed 8 July 2025."},{"key":"1175_CR135","unstructured":"ClinicalTrials.gov. A study evaluating the efficacy and safety of inavolisib + palbociclib + fulvestrant vs placebo + palbociclib + fulvestrant in participants with PIK3CA-mutant, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (INAVO120). https:\/\/clinicaltrials.gov\/study\/NCT04191499. Accessed 8 July 2025."},{"key":"1175_CR136","unstructured":"ClinicalTrials.gov. A study evaluating the efficacy and safety of inavolisib plus CDK4\/6 inhibitor and letrozole vs placebo + CDK4\/6i and letrozole in participants with endocrine-sensitive PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer (INAVO123). https:\/\/clinicaltrials.gov\/study\/NCT06790693. Accessed 8 July 2025."},{"key":"1175_CR137","unstructured":"ClinicalTrials.gov. To evaluate the safety, tolerability, and pharmacokinetics of inavolisib single agent in participants with solid tumors and in combination with endocrine and targeted therapies in participants with breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT03006172. Accessed 8 July 2025."},{"key":"1175_CR138","unstructured":"ClinicalTrials.gov. A study evaluating the efficacy and safety of multiple treatment combinations in participants with breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT04802759. Accessed 3 Apr 2025."},{"key":"1175_CR139","unstructured":"ClinicalTrials.gov. First-in-human study of mutant-selective PI3K\u03b1 inhibitor, RLY-2608, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT05216432. Accessed 8 July 2025."},{"key":"1175_CR140","unstructured":"ClinicalTrials.gov. First-in-human study of STX-478 as monotherapy and in combination with other antineoplastic agents in participants with advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05768139. Accessed 8 July 2025."},{"key":"1175_CR141","unstructured":"ClinicalTrials.gov. Precision therapy for solid tumors: synergistic CDK4\/6 inhibition and anti-VEGF targeting LncRNA (PTST_PALBEVA). https:\/\/clinicaltrials.gov\/study\/NCT06307249. Accessed 8 July 2025."},{"key":"1175_CR142","unstructured":"ClinicalTrials.gov. A phase 1\/2 trial of ARV-471 alone and in combination with palbociclib (IBRANCE\u00ae) in patients with ER+\/HER2- locally advanced or metastatic breast cancer (mBC). https:\/\/clinicaltrials.gov\/study\/NCT04072952. Accessed 15 July 2025."},{"key":"1175_CR143","unstructured":"ClinicalTrials.gov. A study of vepdegestrant (ARV-471, PF-07850327) plus palbociclib versus letrozole plus palbociclib in participants with estrogen receptor positive, human epidermal growth factor negative advanced breast cancer (VERITAC-3). https:\/\/clinicaltrials.gov\/study\/NCT05909397. Accessed 15 July 2025."},{"key":"1175_CR144","unstructured":"ClinicalTrials.gov. A phase I\/II trial to evaluate oral HP568 tablets in patients with ER+\/HER2 advanced breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06757335. Accessed 15 July 2025."},{"key":"1175_CR145","unstructured":"ClinicalTrials.gov. Phase I study to evaluate SIM0270 alone or in combination in ER+, HER2- locally advanced or metastatic breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT05293964. Accessed 15 July 2025."},{"key":"1175_CR146","unstructured":"ClinicalTrials.gov. A phase Ib\/II study to evaluate multiple combination therapies of FWD1802 in patients with ER+\/HER2\u2212 BC. https:\/\/clinicaltrials.gov\/study\/NCT07002177. Accessed 15 July 2025."},{"key":"1175_CR147","unstructured":"ClinicalTrials.gov. A phase I clinical trial of FWD1802 in patients with ER+\/HER2\u2212 BC. https:\/\/clinicaltrials.gov\/study\/NCT06064812. Accessed 15 July 2025."},{"key":"1175_CR148","unstructured":"ClinicalTrials.gov. A comparative study of AZD9833 plus palbociclib versus anastrozole plus palbociclib in patients with ER-positive HER2 negative breast cancer who have not received any systemic treatment for advanced disease (SERENA-4). https:\/\/clinicaltrials.gov\/study\/NCT04711252. Accessed 15 July 2025."},{"key":"1175_CR149","unstructured":"ClinicalTrials.gov. Study of AZD9833 alone or in combination in women with advanced breast cancer (SERENA-1). https:\/\/clinicaltrials.gov\/study\/NCT03616587. Accessed 15 July 2025."},{"key":"1175_CR150","unstructured":"ClinicalTrials.gov. Phase III study to assess AZD9833+ CDK4\/6 inhibitor in HR+\/HER2-MBC with detectable ESR1m before progression (SERENA-6). https:\/\/clinicaltrials.gov\/study\/NCT04964934. Accessed 15 July 2025."},{"key":"1175_CR151","unstructured":"ClinicalTrials.gov. Elacestrant vs elacestrant plus a CDK4\/6 inhibitor in patients with ER-positive\/HER2-negative advanced or metastatic breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06062498. Accessed 15 July 2025."},{"key":"1175_CR152","unstructured":"ClinicalTrials.gov. Open-label umbrella study to evaluate safety and efficacy of elacestrant in various combination in patients with metastatic breast cancer (ELEVATE). https:\/\/clinicaltrials.gov\/study\/NCT05563220. Accessed 15 July 2025."},{"key":"1175_CR153","unstructured":"ClinicalTrials.gov. A study of GDC-9545 alone or in combination with palbociclib and\/or luteinizing hormone-releasing hormone (LHRH) agonist in locally advanced or metastatic estrogen receptor-positive breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT03332797. Accessed 15 July 2025."},{"key":"1175_CR154","unstructured":"ClinicalTrials.gov. A study evaluating the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in participants with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (persevERA Breast Cancer). https:\/\/clinicaltrials.gov\/study\/NCT04546009. Accessed 15 July 2025."},{"key":"1175_CR155","unstructured":"ClinicalTrials.gov. A study to evaluate efficacy and safety of giredestrant compared with fulvestrant (plus a CDK4\/6 inhibitor), in participants with ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy (pionERA Breast Cancer). https:\/\/clinicaltrials.gov\/study\/NCT06065748. Accessed 15 July 2025."},{"key":"1175_CR156","unstructured":"ClinicalTrials.gov. A phase 1 study of oral OP-1250 in combination with palbociclib in HR+\/HER2- breast cancer patients. https:\/\/clinicaltrials.gov\/study\/NCT05266105. Accessed 15 July 2025."},{"key":"1175_CR157","unstructured":"ClinicalTrials.gov. A study of H3B-6545 in combination with palbociclib in women with advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor-2 (HER2)-negative breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT04288089. Accessed 15 July 2025."},{"key":"1175_CR158","unstructured":"ClinicalTrials.gov. A study to examine the safety of different doses of BG-68501 given to participants with advanced-stage tumors. https:\/\/clinicaltrials.gov\/study\/NCT06257264. Accessed 2 Apr 2025."},{"key":"1175_CR159","unstructured":"ClinicalTrials.gov. (VELA) Study of BLU-222 in advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05252416. Accessed 18 Mar 2025."},{"key":"1175_CR160","unstructured":"ClinicalTrials.gov. A study with NKT3447 for adults with advanced\/metastatic solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT06264921. Accessed 2 Apr 2025."},{"key":"1175_CR161","unstructured":"ClinicalTrials.gov. Open-label study to evaluate the safety, tolerability, PK, and efficacy of INX-315 in patients with advanced cancer (INX-315-01). https:\/\/clinicaltrials.gov\/study\/NCT05735080. Accessed 18 Mar 2025."},{"key":"1175_CR162","unstructured":"ClinicalTrials.gov. A study to learn about the study medicine (called PF-07220060 in combination with PF-07104091) in participants with breast cancer and solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05262400. Accessed 18 Mar 2025."},{"key":"1175_CR163","unstructured":"ClinicalTrials.gov. Study to test the safety and tolerability of PF-07220060 in participants with advance solid tumors (CDK4i). https:\/\/clinicaltrials.gov\/study\/NCT04557449. Accessed 2 Apr 2025."},{"key":"1175_CR164","unstructured":"ClinicalTrials.gov. A study to learn about the study medicine PF-07220060 together with letrozole compared to letrozole alone in women post menopause. https:\/\/clinicaltrials.gov\/study\/NCT06465368. Accessed 2 Apr 2025."},{"key":"1175_CR165","unstructured":"ClinicalTrials.gov. A study to learn about the study medicine called PF-07220060 in combination with fulvestrant in people with HR-positive, HER2-negative advanced or metastatic breast cancer who progressed after a prior line of treatment. https:\/\/clinicaltrials.gov\/study\/NCT06105632. Accessed 2 Apr 2025."},{"key":"1175_CR166","unstructured":"ClinicalTrials.gov. Study of PF-07220060 with letrozole in adults with HR-positive HER2-negative breast cancer who have not received anticancer treatment for advanced\/metastatic disease (FourLight-3). https:\/\/clinicaltrials.gov\/study\/NCT06760637. Accessed 2 Apr 2025."},{"key":"1175_CR167","unstructured":"ClinicalTrials.gov. BGB-43395 alone or as part of combination therapies in Chinese participants with HR+\/HER2- breast cancer and other advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT06253195. Accessed 2 Apr 2025."},{"key":"1175_CR168","unstructured":"ClinicalTrials.gov. BGB-43395 alone or as part of combination therapies in participants with breast cancer and other advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT06120283. Accessed 2 Apr 2025."},{"key":"1175_CR169","unstructured":"ClinicalTrials.gov. FIH study of RGT-419B alone and with endocrine therapy in HR-positive, HER2-negative advanced\/metastatic breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT05304962. Accessed 2 Apr 2025."},{"key":"1175_CR170","unstructured":"ClinicalTrials.gov. A phase I study of RGT-419B in patients with HR-positive, HER2-negative advanced breast cancer or other solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT06299124. Accessed 2 Apr 2025."},{"key":"1175_CR171","unstructured":"ClinicalTrials.gov. Evaluation of TQB3616 capsules in a phase II clinical trial for recurrent\/metastatic breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT06702618. Accessed 2 Apr 2025."},{"key":"1175_CR172","unstructured":"ClinicalTrials.gov. Highly selective CDK7 inhibitor Q901 in selected advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05394103. Accessed 2 Apr 2025."},{"key":"1175_CR173","unstructured":"ClinicalTrials.gov. A study to investigate fadraciclib (CYC065), in subjects with advanced solid tumors and lymphoma. https:\/\/clinicaltrials.gov\/study\/NCT04983810. Accessed 2 Apr 2025."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01175-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01175-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01175-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:36Z","timestamp":1764605436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01175-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01175-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pfizer Inc funded the development of this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Richard S. Finn serves as a consultant for AstraZeneca, Bristol Myers Squibb, CStone, Eisai, Exelixis, Eli Lilly, Merck, Novartis, Pfizer, and Roche\/Genentech; has received institutional support from Bristol Myers Squibb, Eisai, Eli Lilly, Merck, Pfizer, and Roche\/Genentech; has received speaker fees from Genentech; has received travel support from Merck, Pfizer, and Roche; and participates on a data safety monitoring board or advisory board for AstraZeneca. Hope S. Rugo serves in a consulting or advisory role for Chugai, Sanofi, Napo Pharmaceuticals, Mylan, and BMS; and has received institutional research funding from AstraZeneca, Daiichi-Sankyo, Inc., F. Hoffmann-La Roche AG\/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, and Ambryx. Javier Cortes\u00a0reports having received personal honoraria for consulting\/advisory from AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Inc., Hexagon Bio; having received honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics; having received institutional research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London; stock of MedSIR, MAJ3 Capital, Leuko (relative); having personal support for attending meetings and\/or travel from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics; and patents: Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294 A. ISSUED; Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cort\u00e9s.US 2019\/0338368 A1. LICENSED. Sibylle Loibl has received grants and\/or honorarium for ad boards and\/or contracts from AstraZeneca, AbbVie, Agendia, Amgen, BionTech, Celgene\/Bristol Myers Squibb, Cellcuity, Daiichi-Sankyo, Inc., Exact Sciences, Gilead, GlaxoSmithKline, Incyte, Lilly, Medscape, Molecular Health, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Relay, Roche, Sanofi, Seagen, Stemline\/Menarini, Olema, Bayer, Bicycle, JAZZ Pharma, and BeiGene; has received support for attending meetings and\/or travel from Daiichi-Sankyo, Inc., the European Society for Medical Oncology, St. Gallen Breast Cancer Consortium, the American Society of Clinical Oncology, and Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Kommission Mamma; has planned, issued, or pending patents: EP14153692.0 \/ EP21152186.9 \/ EP18209672 \/ EP24210258; and has received royalties from VM Scope. Grace Foley, Eric Gauthier, Yao Wang, Sindy Kim, and Lars Anders are employees and stockholders of Pfizer Inc. Dennis J. Slamon has received nonfinancial support and other support from BioMarin, grants, nonfinancial support, and other support from Pfizer and Novartis, personal fees from Eli Lilly, and other support from Amgen, Seattle Genetics, 1200 Pharma, and TORL BioTherapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors contributed to the study conception and design. All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}